163 related articles for article (PubMed ID: 35468621)
21. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
24. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
Ishikawa T; Okayama T; Sakamoto N; Ideno M; Oka K; Enoki T; Mineno J; Yoshida N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Kokura S; Uno K; Naito Y; Itoh Y
Int J Cancer; 2018 Jun; 142(12):2599-2609. PubMed ID: 29388200
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.
Vey N; Delaunay J; Martinelli G; Fiedler W; Raffoux E; Prebet T; Gomez-Roca C; Papayannidis C; Kebenko M; Paschka P; Christen R; Guarin E; Bröske AM; Baehner M; Brewster M; Walz AC; Michielin F; Runza V; Meresse V; Recher C
Oncotarget; 2016 May; 7(22):32532-42. PubMed ID: 27081038
[TBL] [Abstract][Full Text] [Related]
29. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
30. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
31. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
32. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
33. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission.
Vey N; Bourhis JH; Boissel N; Bordessoule D; Prebet T; Charbonnier A; Etienne A; Andre P; Romagne F; Benson D; Dombret H; Olive D
Blood; 2012 Nov; 120(22):4317-23. PubMed ID: 23002117
[TBL] [Abstract][Full Text] [Related]
34. Studies in acute leukemia. I. Antibody-dependent and spontaneous cellular cytotoxicity by leukemic blasts from patients with acute nonlymphoid leukemia.
Fernandes G; Garrett T; Nair M; Straus D; Good RA; Gupta S
Blood; 1979 Sep; 54(3):573-80. PubMed ID: 288485
[TBL] [Abstract][Full Text] [Related]
35. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
36. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
37. Antibody-targeted therapy for myeloid leukemia.
Appelbaum FR
Semin Hematol; 1999 Oct; 36(4 Suppl 6):2-8. PubMed ID: 10530710
[TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
40. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]